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Introduction
Thiamine is a major cofactor involved in energy metabolism in brain tissue. In humans, at least four forms of thiamine are known, namely free-thiamine (free-T), thiamine monophosphate (TMP), thiamine diphosphate (TDP), and thiamine triphosphate (TTP) (Gangolf et al., 2010) . Both free-T and TMP forms are absorbed in the small intestine by two specific transporters: thiamine transporter-1 (hTHTR1, encoded by SLC19A2) and thiamine transporter-2 (hTHTR2, encoded by SLC19A3) (Rajgopal et al., 2001; Subramanian et al., 2006; Mayr et al., 2011) . In the blood-brain barrier and the choroid plexus, hTHTR2 is expressed in the pericytes surrounding endothelial cells, while hTHTR1 is localized to the luminal side; this supports their role in the transport of thiamine into the CNS (Kevelam et al., 2013) .
Thiamine is converted into TDP, the metabolically active form of thiamine, by a specific kinase (thiamine phosphokinase, TPK, EC 2.7.4.15) (Tallaksen et al., 1991; Zhao et al., 2002; Banka et al., 2014) . TDP may act as a cofactor in the cytosol (transketolase, EC, 2.2.1.1), in peroxisomes (2-hydroxyacyl-CoA lyase, EC, 4.1.2.n2), or it can enter the mitochondria through another transporter encoded by the SLC25A19 and be a cofactor for pyruvate dehydrogenase (EC, 1.2.4.1), 2-oxoglutarate dehydrogenase (EC, 1.2.4.2), and branched-chain alpha-keto acid dehydrogenase (EC, 1.2.4.4) (Mayr et al., 2011) .
Thiamine transporter-2 deficiency (hTHTR2 deficiency) (OMIM#607483) is a recessive inherited disease caused by mutations in SLC19A3. It presents in normally developing children as episodes of acute and recurrent encephalopathy, dystonia, seizures and brain lesions in the cerebral cortex, basal ganglia, thalami, brainstem and cerebellum (Ozand et al., 1998; Gerards et al., 2013; Kevelam et al., 2013) . Early administration of biotin and thiamine in patients with hTHTR2 deficiency can potentially reverse the clinical and radiological abnormalities and improve neurological outcome (Kono et al., 2009; Debs et al., 2010; Serrano et al., 2012; Alfadhel et al., 2013; Pérez-Dueñ as et al., 2013; Tabarki et al., 2013; Distelmaier et al. 2014; Haack et al., 2014) .
To date, non-specific biochemical abnormalities (i.e. increases of 2-oxoglutarate, lactate, and alanine in biological fluids, and a lactate peak on spectroscopy) have been reported in hTHTR2 patients (Serrano et al., 2012; Kevelam et al., 2013; Gerards et al., 2013; Distelmaier et al., 2014; Haack et al., 2014) . Because hTHTR2 deficiency is a potentially treatable disorder, there is an urgent need for a robust biomarker to allow prompt diagnosis and treatment monitoring of this disease.
The aims of this study were: (i) to establish reference values for thiamine derivatives in blood and CSF; (ii) compare these results with a cohort of children with Leigh syndrome, six of them harbouring mutations in the SLC19A3 gene, and children with other acquired and genetic neurological conditions; and (iii) establish assays for thiamine derivatives in fibroblast cultures to confirm the diagnosis of patients with mutations in SLC19A3.
This study was conducted with the approval of the institutional review boards of the Hospital Sant Joan de Déu, Hospital Clinic and the Autonomous University of Madrid. Written informed consent was obtained from the parents or guardians of all enrolled patients and participants. This study was conducted following the STARD guidelines of diagnostic accuracy (first official version, January 2003) as recommended for fluid biomarkers in neurological disorders (Gnanapavan et al., 2014) .
Materials and methods

Study population
Blood and CSF samples from control subjects
Reference values for free-T, TMP and TDP were established in 106 whole blood samples and 38 CSF samples from paediatric control subjects (Supplementary material). CSF/whole blood ratios for free-T, TMP and TDP were determined in nine subjects for whom lumbar puncture and venous puncture were performed on the same day. The CSF samples were frozen at À80 C and protected from light until analysis.
Patients with mutations in SLC19A3
We studied CSF thiamine derivatives in six patients with Leigh encephalopathy and SLC19A3 mutations (Table 1) . Lumbar puncture was performed before thiamine treatment in all patients except in Patient 3, who was receiving 24 mg/kg/day of thiamine. A blood sample before thiamine treatment was only available for Patient 6. Five patients (Patients 1, 2, 3, 4 and 6) were treated with thiamine after 3 to 28 days following the onset of acute encephalopathy (mean age 8 years, range 1 month to 15 years). Patients 1, 3, 4 and 6 showed a dramatic improvement of symptoms in the short term, whereas Patient 2 evolved into a drug-resistant status dystonicus and died from septicaemia. Patient 5, the older brother of Patient 4, who had a disease onset at 3 months of life, was treated at age 11 with no significant changes on his motor disability but with improved alertness as perceived by his parents. His follow-up MRI 13 months after thiamine supplementation showed regression of the cortical-subcortical changes in cerebral hemispheres and cerebellum. Clinical description of Patients 1, 2 and 3 has been previously published in Ortigoza-Escobar et al. (2014) . Biomarkers of mitochondrial dysfunction were analysed in blood, urine and CSF samples, when available, and compared with reference values that were previously established in our laboratory (Artuch et al., 1995) .
Patients with Leigh syndrome and other disorders of the CNS
To test the specificity of CSF thiamine as a biomarker for SLC19A3 defects, we analysed CSF samples obtained from 10 patients with Leigh syndrome who were not on thiamine treatment (Table 2 ). We also included 49 patients with several acquired or genetic neurologic diseases (Supplementary material).
Fibroblast samples
We analysed nine human fibroblast cell lines from three patients with SLC19A3 mutations (Patients 1, 2 and 6) and six patients with other inborn errors of metabolism that were used as controls.
Compliance with ethical guidelines
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki of 1975, as revised in 2000. Informed consent for participation in the study was obtained from all patients.
Procedures
Procedures are detailed in the Supplementary material and Supplementary Fig. 1 .
Results
Reference values for thiamine derivatives in whole blood and CSF samples
Within-run and between-run imprecision data, quantification limits, detection limits and analytical intervals for free-T, TMP and TDP are reported in Supplementary Table 1 .
Reference values for free-T, TMP and TDP in blood were established. A negative correlation was observed between TDP concentration and age (r = À0.290, P = 0.003). Consequently, blood values were stratified into two different age groups (Fig. 1A) .
A negative correlation between free-T and age was observed in the CSF (r = À0.64, P 5 0.01); thus, three reference intervals were established (Table 1 and Fig. 1B) . Significant correlations were found between the CSF and whole blood concentrations of TDP (r = 0.746, P = 0.001) and TMP (r = 0.601, P = 0.039). The median CSF/wholeblood ratios for TDP, TMP and free-T in the control samples were 0.04 (range: 0.01-0.09), 3.2 (range: 1.3-7.0) and 1.8 (range: 0.9-3.6), respectively, indicating the most prevalent thiamine form in each fluid.
Thiamine forms in whole blood and CSF from patients with mutations in SLC19A3 Before thiamine treatment, very low concentrations of free-T were found in the CSF samples of five patients (Table 1 and Fig. 1B) . The values of the different thiamine forms in the CSF of Patient 3, who was on thiamine supplementation, were above the reference range.
The concentrations of TDP (105 nmol/l), TMP (8.4 nmol/ l), and free-T (21.5 nmol/l) in the whole blood of Patient 6 before thiamine supplementation were within the control range, but the CSF/blood free-T ratio was low (0.22 versus 0.9-3.6 for control population).
Thiamine forms in CSF from patients with Leigh syndrome and other disorders of the CNS Molecular studies ruled out the presence of mutations in SLC19A3 in the 10 patients with Leigh syndrome. Three of them had free-T values below the reference range, but deficiencies were milder than those of patients with SLC19A3 mutations (Table 2 ). Similarly, 6 of 49 patients with other neurological conditions showed CSF free-T levels that were slightly below the lower range of reference ( Supplementary Fig. 2 ): perinatal asphyxia (2 years, 20.9 nmol/l and 13 years, 12.3 nmol/l), genetic epileptic encephalopathy (2 years, 15.0 nmol/l and 1 year, 19.0 nmol/l), encephalitis (1 year, 12.0 nmol/l) and spastic paraparesia (1 year, 13.9 nmol/l).
Thiamine forms, pyruvate dehydrogenase complex activity and mitochondrial substrate oxidation rates in fibroblasts When the fibroblasts of Patients 1, 2 and 6 were cultured for 10 days in a medium with a low concentration of thiamine (2.8 nmol/l), significant reduced intracellular concentrations of all thiamine derivatives were observed as compared to the control group ( Fig. 2A) . TDP was the main intracellular form, both in patients and controls, though differences among these groups were relevant (P = 0.02) (Fig. 2A) . When fibroblasts were cultured in a medium containing thiamine (304.3 nmol/l), all the thiamine forms normalized (Fig. 2B) . Surprisingly, substrate oxidation rates and pyruvate dehydrogenase complex activity were similar in fibroblasts from hTHTR2 patients and controls when analysed in low thiamine medium (Supplementary Table 2 ). 
Discussion
hTHTR2 deficiency is a genetic disorder that leads to acute encephalopathy and brain damage in childhood, mimicking intractable causes of Leigh syndrome caused by mitochondrial respiratory chain defects (Gerards et al., 2013; Kevelam et al., 2013; Distelmaier et al., 2014; Haack et al., 2014) . Recently, several studies have focused on the increasing phenotypic spectrum of hTHTR2 deficiency and on therapeutic interventions. Overall, previously published literature suggests a clear benefit of early thiamine and biotin administration in the short-term, and less effective results of late treatment initiation when the patient is already severely affected (Gerards et al., 2013) .
In this setting, we underline the necessity of developing biochemical biomarkers for hTHTR2 defects that would allow early diagnosis and timely therapeutic intervention. For this purpose, we first established control values for thiamine derivatives in blood and CSF in a paediatric population. Subsequently, we determined blood and CSF thiamine concentrations in a cohort of patients with SLC19A3 mutations and compared them with patients with Leigh syndrome who were negative for SLC19A3 mutations and other neurological conditions.
Currently, several HPLC procedures have been published to measure the concentrations of thiamine and its esters (Tallaksen et al., 1991; Kö rner et al., 2009; Mayr et al., 2011) . Here, we present a modified HPLC procedure for free-T, TMP and TDP analyses.
We observed a strong correlation between CSF and whole blood concentrations of the different thiamine forms. Moreover, free-T and TMP were more concentrated in CSF than in whole blood. These forms may serve as a thiamine reservoir for the brain, and consequently, their measurement might be more sensitive for the identification of hTHTR2-deficient patients. In line with this hypothesis, free-T was severely reduced in the CSF of hTHTR2-deficient patients before the introduction of thiamine supplementation (Fig. 1B) . In contrast, free-T concentrations were slightly reduced in 9 of 59 (15.2%) patients with acquired or inherited disorders of the CNS, three of them being Leigh syndrome patients. Secondary thiamine deficiency in these children may be due to a combination of several mechanisms, including increased oxidative stress and thiamine turnover, inflammatory cell activation and drug interactions. Similarly, CSF folate deficiency has been observed in children with mitochondrial disorders and other neurological conditions bearing no primary relation to folate transport or metabolism (Pé rez-Dueñ as et al., 2011).
We then analysed the intracellular concentrations of thiamine in hTHTR2-deficient fibroblasts cultured in a low thiamine medium. Markedly reduced concentrations of all thiamine forms were observed when compared to controls ( Fig. 2A) . However, TDP concentrations were relatively preserved as compared to free-T and TMP, suggesting that the small amounts of thiamine that entered the cell were almost completely converted to TDP, probably due to the high-binding affinity of the TPK enzyme for its substrate, thiamine (Onozuka et al., 2003) . Remarkably, when fibroblasts were cultured in a medium containing normal amounts of thiamine all the thiamine forms normalized (Fig. 2B ), but TMP remained lower than the other forms, reflecting its quick conversion TDP.
Surprisingly, pyruvate dehydrogenase complex (PDHc) activities and mitochondrial substrate oxidation rates in fibroblasts cultured in a low thiamine medium were similar to those in controls (Supplementary Table 2 ). We speculate that residual TDP concentrations were sufficient to normalize the thiamine-dependent enzymatic activities in standard conditions, but would not be able to do so under stress situations, as those that trigger acute decompensations in hTHTR2 patients. In line with this hypothesis, fibroblasts from hTHTR2-deficient patients showed a substantially reduced capacity to increase SLC19A3 expression in situations of hypoxia or acidosis (Schä nzer et al., 2014) . Mayr et al. (2011) analysed the thiamine forms in muscle, blood and fibroblasts of seven patients with TPK deficiency. They found a reduction of TDP in all tissue and blood samples from patients but normal levels of free-T and TMP. Recently, Banka et al. (2014) corroborated these results in frozen muscle biopsy samples from another TPK-deficient patient.
Taken together, these findings suggest that intracellular quantification of thiamine forms may be useful for distinguishing different genetic defects in thiamine transport and metabolism (Mayr et al., 2011) .
The in vitro analysis of aberrant pre-messenger RNA splicing due to the c.980-14A4G allele showed the total exclusion of exon 4 and a predicted severe impairment of hTHTR2 function (Supplementary material). Hence, in our two hTHTR2 patients carrying loss-of-function mutations in both alleles, thiamine uptake from fibroblasts is probably compensated by the upregulation of an alternative transport system. Other human thiamine transporters, such as the reduced folate carrier (RFC1) and the hTHTR1 (Zhao et al., 2002) , or the organic cation transporter (OCT1), recently identified as an important contributor to the uptake of thiamine from blood to tissues (Kato et al., 2015) , could compensate for the thiamine transport in hTHTR2-deficient patients.
Four patients with SLC19A3 mutations in our series responded extremely well to thiamine overload during the acute encephalopathic episode and symptoms improved within hours or days (Table 1 ). All four patients are stable and have not experienced neurological recurrences since the initiation of treatment. Three of these patients (Patients 1, 3 and 4) harboured missense mutations in SLC19A3, whereas Patient 6 was heterozygous for two null mutations p.Ser26Leufs*19 and p.Gly327Aspfs*8. Previously, thiamine responsiveness was also reported in a Leigh-like encephalopathic infant that was homozygous for the p.Ala328Leufs*10 frameshift mutation in SLC19A3 (Haack et al., 2014) .
A lumbar puncture was performed on Patient 3 who was receiving 24 mg/kg/day of thiamine, and CSF analysis showed free-T values high above the upper limit of reference range (Fig. 1B) . Again, our findings suggest that thiamine supplementation can compensate the hTHTR2 defect and restore thiamine values in the CSF. Theoretically, CSF free-T could be used to monitor treatment and optimize thiamine dose in hTHTR2 patients showing poor clinical response. In contrast to this, whole-blood thiamine is useful to monitor adherence to therapy in patients who are metabolically compensated, in whom repeated lumbar punctures are not appropriate because of ethical reasons (Ortigoza-Escobar et al., 2014) .
Mitochondrial biomarkers were normal in all but one hTHTR2 patient who showed increased plasma and CSF levels of lactate, high plasma levels of alanine, leucine and isoleucine, and a high excretion level of alpha-ketoglutarate in urine (Table 1) . Interestingly, that patient experienced the earliest onset of encephalopathy and showed a severe reduction of CSF thiamine levels. Other authors reported high lactate values and high organic acid excretion levels in infants with Leigh-like phenotypes (Gerards et al., 2013; Kevelam et al., 2013; Schä nzer et al., 2014) but normal values in older patients with the biotin-thiamine-responsive basal ganglia phenotype (Ozand et al., 1998; Zeng et al., 2005; Kono et al., 2009; Debs et al., 2010; Tabarki et al., 2013; Distelmaier et al., 2014) . Therefore, the currently available mitochondrial biomarkers are not sensitive for all hTHTR2-related phenotypes.
In conclusion, children with hTHTR2 deficiency have remarkable free-T deficiency in CSF and fibroblasts. Thiamine supplementation in these children restores CSF and intra-cellular thiamine levels, probably through an alternative transport system. We recommend that patients presenting with Leigh syndrome be promptly treated with a vitamin cocktail including thiamine and biotin and that a lumbar puncture be performed before the empirical administration of vitamins. Very low values of free-T in the CSF and/or a good therapeutic response to thiamine supplementation should lead clinicians to consider a genetic analysis of the SLC19A3 gene.
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